GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tsumura & Co (OTCPK:TSMRF) » Definitions » Total Liabilities

Tsumura (Tsumura) Total Liabilities : $887 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Tsumura Total Liabilities?

Tsumura's Total Liabilities for the quarter that ended in Mar. 2024 was $887 Mil.

Tsumura's quarterly Total Liabilities declined from Sep. 2023 ($865.23 Mil) to Dec. 2023 ($841.39 Mil) but then increased from Dec. 2023 ($841.39 Mil) to Mar. 2024 ($887.01 Mil).

Tsumura's annual Total Liabilities increased from Mar. 2022 ($783.22 Mil) to Mar. 2023 ($931.94 Mil) but then declined from Mar. 2023 ($931.94 Mil) to Mar. 2024 ($887.01 Mil).


Tsumura Total Liabilities Historical Data

The historical data trend for Tsumura's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tsumura Total Liabilities Chart

Tsumura Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 910.15 790.20 783.22 931.94 887.01

Tsumura Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 931.94 893.80 865.23 841.39 887.01

Tsumura Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Tsumura's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=457.6+(362.952+61.895
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+4.559)
=887

Total Liabilities=Total Assets (A: Mar. 2024 )-Total Equity (A: Mar. 2024 )
=2858.484-1971.478
=887

Tsumura's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=457.6+(362.952+61.895
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+4.559)
=887

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=2858.484-1971.478
=887

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tsumura Total Liabilities Related Terms

Thank you for viewing the detailed overview of Tsumura's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Tsumura (Tsumura) Business Description

Traded in Other Exchanges
Address
2-17-11, Akasaka, Minato-ku, Tokyo, JPN, 107-8521
Tsumura & Co is a specialty and generic drug manufacturing company. The company generates most of its revenue through prescription Kampo products, followed by over-the-counter medicines. Tsumura promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers. The company considers strategic collaboration agreements to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Tsumura (Tsumura) Headlines

From GuruFocus

Q2 2020 Tsumura & Co Earnings Presentation Transcript

By GuruFocus Research 02-15-2024